Kelun Pharmaceutical: Net profit expected to decrease by 42.03% year-on-year in 2025, with a proposed dividend of 4.68 RMB per 10 shares

People’s Finance News April 2, Lunz Pharmaceutical (002422) disclosed its annual report on April 2. In 2025, the company recorded total operating revenue of 18.51B yuan, down 15.13% year over year; net profit attributable to shareholders was 1.7B yuan, down 42.03% year over year. Basic earnings per share were 1.07 yuan. The company plans to distribute a cash dividend of 4.68 yuan (tax included) for every 10 shares. During the reporting period, the main reasons for changes in operating performance were: for infusion and non-infusion pharmaceutical products, a decline in terminal market demand led to a reduction in product sales volume, and the impact of centralized procurement, resulting in a year-over-year decline in profit; for Chuan Nining Bio and penicillin products, falling product prices led to a decrease in sales volume of some products, and new product R&D and trial production increased expenses, resulting in a year-over-year decline in profit; for Colun Botai Bio, sales revenue from innovative drug products grew significantly, but profit declined year over year due to reduced license and milestone income and increased R&D expenses; and decreased profits from equity-method investees, leading to a year-over-year decline in investment income.